Melbourne, Australia, 12 January 2020: Certa Therapeutics, a biotechnology company focused on improving lives by developing innovative precision treatments for inflammatory and fibrotic diseases,is pleased to announce the attendance of the senior management team including Chief Executive Officer, Professor Darren Kelly, at the 38th J.P. Morgan Healthcare Conference.
The conference will be held between 13-16 January 2020 in San Francisco, California. Certa Therapeutics are attending following continued discussions with J.P. Morgan and other biotechnology investment firms. During the conference the Certa team will highlight their scientific advancements in the treatment of systemic sclerosis (SSc) and chronic kidney disease (CKD).
Certa Therapeutics is progressing its clinical development program for its novel therapeutic platform of precision medicines for treating SSc and CKD. Certa is using genetic analysis to identify the most suitable patients for treatment.
SSc is a rare autoimmune disease, causing inflammation and fibrosis (scarring/hardening) of the skin and other organs. There is a clear need for new innovative treatments as currently approved therapies are largely ineffective and can have significant side-effects.
There are currently no treatments available for kidney fibrosis, which presents in the majority of patients with CKD. Given the enormous cost of dialysis and kidney transplants to the healthcare system, finding an effective treatment for these patients remains one of the global healthcare industry’s largest unmet needs.
The J.P. Morgan Healthcare Conference is the largest healthcare investment conference in the United States. It brings together industry leaders, investors, fast-growth companies, and emerging technology creators in healthcare. This Conference will provide Certa a unique platform to share its innovative treatment advancements with investors and industry leaders in the biotech and pharmaceutical sector.